Wenling Innovative Biopharmaceutical Technology

Wenling Innovative Biopharmaceutical Technology is a Chinese biotechnology company focused on the development of innovative therapies for metabolic and endocrine disorders. The company specializes in the research of long-acting protein drugs and small molecule candidates targeting metabolic pathways such as GLP-1 and FGF21. Based in Wenling, Zhejiang, the firm leverages its internal R&D capabilities to advance a pipeline of treatments for prevalent conditions including type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Their business model centers on the discovery and early-stage development of high-value biopharmaceuticals to address unmet medical needs in the metabolic health space.